News!

We have started the  501(c)3 (non-profit) filing procedure!  We now have our EIN and Articles of Incorporation have been approvedWe're now a Virginia Corporation!  Lot's of paperwork and IRS approvals but we're getting closer.

Cushing's Info

It's About Time There Was Some Support!

 
Total Members : 608
Latest Member : reneestout
This Week : 3 Registers
This Month : 2 Registers

Members Online

None
" This site is invaluable to anyone suffering. The amount of information can be overwhelming because it is so plentiful. The forum is wonderful. Up to date information, wonderful people who give help, information; support and Hope! "
KimS

Member Login






Login reminder Forgot login?
Register Register
<<  September 2010  >>
 Su  Mo  Tu  We  Th  Fr  Sa 
     1  2  4
  5  6  7  8  91011
12131415161718
1920222324
2627282930  
02
Mar
2010
Cushing Syndrome in the McCune-Albright Syndrome
smaller text tool iconmedium text tool iconlarger text tool icon

Rebecca J. Brown, Marilyn H. Kelly,  and Michael T. Collins*

Clinical Endocrinology Branch (R.J.B.), National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20814; and Skeletal Clinical Studies Unit (M.H.K., M.T.C.), Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892

* To whom correspondence should be addressed. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Context: Cushing syndrome (CS) is a rare but potentially fatal feature of McCune-Albright syndrome (MAS). Optimal management, prognostic features, and long-term follow-up of this disorder have not been described.

Setting: The study was conducted at an academic tertiary care center.

Patients: A total of 112 patients participating in a natural history study at the National Institutes of Health (NIH) were evaluated, and 21 published cases were reviewed.

Interventions: Subjects received observation, medical management, or bilateral adrenalectomy.

Main Outcome Measures: We measured prevalence, prognostic factors, and natural history.

Results: The prevalence of CS among NIH patients was 7.1%. The median age at diagnosis was 3 months. Clinical features included "Cushingoid facies" (66.7%), failure to thrive (60.0%), low birth weight (50.0%), liver disease (36.7%), and heart disease (26.7%). Six patients (20.0%) died, four after adrenalectomy. Death was more likely in patients with comorbid heart disease (odds ratio, 13.3; P < 0.05). Of 23 survivors, 13 underwent adrenalectomy, and 10 exhibited spontaneous resolution. Two patients with spontaneous resolution who were tested later in life (3 and 15 yr after resolution) continued to have low-level, autonomous adrenal function with biochemical adrenal insufficiency. Compared to MAS patients without CS, patients with CS were more likely to have a cognitive/developmental disorder (44.4 vs. 4.8%; P < 0.001; odds ratio, 8.8).

Conclusions: Comorbid heart and liver disease were poor prognostic markers and may indicate the need for prompt adrenalectomy. The high incidence of cognitive disorders indicates a need for close developmental follow-up and parental counseling. Patients with spontaneous resolution of CS may develop adrenal insufficiency, and they require long-term monitoring.

From http://jcem.endojournals.org/cgi/content/abstract/jc.2009-2321v1

 
You Might Also Like...

Find It!

Discuss!

Did you find this information useful?
All site features are available free of charge thanks to the kind support of our donors,
many of them Cushing's patients, friends and family.
No forms of advertising are used on Cushie.info.
All donations are gratefully accepted!

Site Design and Maintenance: Mary O'Connor, Founder and Webmaster

Copyright © 2000-2010 Cushings Help Organization, Inc. All rights reserved.